AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2022
Sep 6, 2022
31523_dirs_2022-09-06_a59ce506-e7ae-40fa-92df-c0c3a1e7f0d0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2022-09-01
Reporting Person: Quimi Daphne (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-09-01 | Common Stock | S | 4397 | $11.2851 | Disposed | 335312 | Direct |
Footnotes
F1: The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.99 to $11.57. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.